CA2929650C - 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use - Google Patents

4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use Download PDF

Info

Publication number
CA2929650C
CA2929650C CA2929650A CA2929650A CA2929650C CA 2929650 C CA2929650 C CA 2929650C CA 2929650 A CA2929650 A CA 2929650A CA 2929650 A CA2929650 A CA 2929650A CA 2929650 C CA2929650 C CA 2929650C
Authority
CA
Canada
Prior art keywords
pyrazol
fluoro
indol
indole
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2929650A
Other languages
English (en)
French (fr)
Other versions
CA2929650A1 (en
Inventor
Stefano Crosignani
Sandra CAUWENBERGHS
Frederik Deroose
Gregory DRIESSENS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iteos Belgium SA
Original Assignee
Iteos Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/076,016 external-priority patent/US9126984B2/en
Application filed by Iteos Therapeutics SA filed Critical Iteos Therapeutics SA
Publication of CA2929650A1 publication Critical patent/CA2929650A1/en
Application granted granted Critical
Publication of CA2929650C publication Critical patent/CA2929650C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2929650A 2013-11-08 2014-11-07 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use Expired - Fee Related CA2929650C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP13192224 2013-11-08
US14/076,016 US9126984B2 (en) 2013-11-08 2013-11-08 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
EP13192224.7 2013-11-08
US14/076,016 2013-11-08
BE201400845 2014-11-03
BE2014/0845 2014-11-03
PCT/EP2014/074099 WO2015067782A1 (en) 2013-11-08 2014-11-07 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use

Publications (2)

Publication Number Publication Date
CA2929650A1 CA2929650A1 (en) 2015-05-14
CA2929650C true CA2929650C (en) 2017-08-22

Family

ID=53040940

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929650A Expired - Fee Related CA2929650C (en) 2013-11-08 2014-11-07 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use

Country Status (4)

Country Link
EP (1) EP3066090A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016535097A (cg-RX-API-DMAC7.html)
CA (1) CA2929650C (cg-RX-API-DMAC7.html)
WO (1) WO2015067782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
MA44759B1 (fr) * 2016-04-29 2024-01-31 Bayer Pharma AG Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide
EP3269714A1 (en) 2016-07-13 2018-01-17 Netherlands Translational Research Center B.V. Inhibitors of tryptophan 2,3-dioxygenase
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES
ES2994655T3 (en) * 2020-07-06 2025-01-29 Univ Claude Bernard Lyon Indole derivatives and uses thereof for treating a cancer
WO2023235809A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company Cgas inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0516156D0 (en) * 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
WO2010008427A1 (en) 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
EP2451811A1 (en) 2009-05-27 2012-05-16 F. Hoffmann-La Roche AG Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
BR112012006956A2 (pt) 2009-10-12 2015-09-15 Bayer Cropscience Ag 1- (pirida-3-il) -pirazóisol e 1- (pirimida-5-il) - pirazóisol como pesticidas
AU2011270807A1 (en) * 2010-06-23 2013-01-31 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of ATR kinase

Also Published As

Publication number Publication date
EP3066090A1 (en) 2016-09-14
WO2015067782A1 (en) 2015-05-14
JP2016535097A (ja) 2016-11-10
CA2929650A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
US20160263087A1 (en) Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
US9126984B2 (en) 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
KR102013512B1 (ko) 신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법
CA2929650C (en) 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
US9758505B2 (en) 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
KR20230171979A (ko) Bcl6 단백질 분해의 조절제 및 관련 사용 방법
CA2994917A1 (en) 3-indol substituted derivatives, pharmaceutical compositions and methods for use
NO324519B1 (no) Alifatisk nitrogenholdig 5-kantet ring-forbindelse
CA2998705A1 (en) 1-phenylpyrrolidin-2-one derivatives as perk inhibitors
CN117177974A (zh) 含咪唑稠环类衍生物、其制备方法及其在医药上的应用
WO2015155358A1 (en) Mif inhibitors
JP2019001715A (ja) 三環性化合物
CN115485273B (zh) 作为sstr4激动剂的n-(杂环基和杂环基烷基)-3-苯甲基吡啶-2-胺衍生物
EP2476682A1 (en) 8-oxodihydropurine derivative
JP2022543690A (ja) 架橋ヘテロシクリル置換ピリミジン化合物、その調製方法、及びその薬学的使用
EP3013333A1 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c
TW202409011A (zh) 人類呼吸道融合病毒及間質肺病毒抑制劑
HK1173145A (en) 8-oxodihydropurine derivative

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160504

MKLA Lapsed

Effective date: 20181107